Insider Transactions

INCYTE CORP (INCY) Insider Transactions

Over the last 12 months, 26 INCYTE CORP (INCY) insiders filed 226 SEC Form 4 transactions — $0 in open-market purchases ( 0 distinct buyers) and $43.5M in open-market sales. 1% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.

Recent Form 4 Filings Most recent 50 of 226 (1-year window)

Each row is a single Form 4 filing event for INCY, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.

Date Insider Title Type SEC Code Value Shares Price
2026-06-08 BAKER BROS. ADVISORS LP Grant A $0 1,642 $0.00
2026-06-08 BAKER BROS. ADVISORS LP Grant A $0 1,642 $0.00
2026-06-08 BAKER BROS. ADVISORS LP Grant A $0 6,111 $0.00
2026-06-08 BAKER BROS. ADVISORS LP Grant A $0 6,111 $0.00
2026-06-08 HARRIGAN EDMUND Grant A $0 1,642 $0.00
2026-06-08 HARRIGAN EDMUND Grant A $0 6,111 $0.00
2026-06-08 Clancy Paul J Grant A $0 1,642 $0.00
2026-06-08 Clancy Paul J Grant A $0 6,111 $0.00
2026-06-08 FOUSE JACQUALYN A Grant A $0 1,642 $0.00
2026-06-08 FOUSE JACQUALYN A Grant A $0 6,111 $0.00
2026-06-08 BIENAIME JEAN JACQUES Grant A $0 1,642 $0.00
2026-06-08 BIENAIME JEAN JACQUES Grant A $0 6,111 $0.00
2026-06-08 High Katherine A Grant A $0 1,642 $0.00
2026-06-08 High Katherine A Grant A $0 6,111 $0.00
2026-06-08 BRAWLEY OTIS W Grant A $0 1,642 $0.00
2026-06-08 BRAWLEY OTIS W Grant A $0 6,111 $0.00
2026-06-04 Tray Thomas Principal Accounting Officer Exercise M $221.2K 2,639 $83.83
2026-06-04 Tray Thomas Principal Accounting Officer Exercise M $0 2,639 $0.00
2026-06-04 Tray Thomas Principal Accounting Officer Sell S $263.9K 2,639 $100.00
2026-06-01 CAGNONI PABLO J President, Global Head of R&D Other F $2.4M 25,469 $95.59
2026-05-26 BIENAIME JEAN JACQUES Exercise M $1.3M 15,000 $84.53
2026-05-26 BIENAIME JEAN JACQUES Exercise M $0 15,000 $0.00
2026-05-26 BIENAIME JEAN JACQUES Other F $1.3M 13,059 $97.10
2026-05-26 Tray Thomas Principal Accounting Officer Sell S $199.7K 2,051 $97.35
2026-05-19 Clancy Paul J Exercise M $1.3M 15,000 $84.53
2026-05-19 Clancy Paul J Exercise M $0 15,000 $0.00
2026-05-19 Clancy Paul J Sell S $1.4M 15,000 $94.93
2026-05-08 BAKER BROS. ADVISORS LP Exercise M $1.3M 15,000 $84.53
2026-05-08 BAKER BROS. ADVISORS LP Exercise M $1.3M 15,000 $84.53
2026-05-08 BAKER BROS. ADVISORS LP Exercise M $0 15,000 $0.00
2026-05-08 BAKER BROS. ADVISORS LP Exercise M $0 15,000 $0.00
2026-05-04 Upadhyay Suketu EVP & Chief Financial Officer Grant A $0 26,343 $0.00
2026-05-04 Upadhyay Suketu EVP & Chief Financial Officer Grant A $0 38,429 $0.00
2026-05-04 Upadhyay Suketu EVP & Chief Financial Officer Grant A $0 13,171 $0.00
2026-04-17 CAGNONI PABLO J President, Global Head of R&D Exercise M $390.4K 6,077 $64.25
2026-04-17 CAGNONI PABLO J President, Global Head of R&D Exercise M $905.6K 12,590 $71.93
2026-04-17 CAGNONI PABLO J President, Global Head of R&D Exercise M $0 6,077 $0.00
2026-04-17 CAGNONI PABLO J President, Global Head of R&D Exercise M $0 12,590 $0.00
2026-04-17 CAGNONI PABLO J President, Global Head of R&D Sell S $1.8M 18,667 $96.50
2026-04-15 Meury William Chief Executive Officer Exercise M $0 125,000 $0.00
2026-04-15 CAGNONI PABLO J President, Global Head of R&D Grant A $0 27,892 $0.00
2026-04-15 Stein Steven H CMO & Head of Late-Stage Dev. Grant A $0 39,049 $0.00
2026-03-31 BAKER BROS. ADVISORS LP Grant A $0 421 $0.00
2026-03-31 BAKER BROS. ADVISORS LP Grant A $0 421 $0.00
2026-03-31 HARRIGAN EDMUND Grant 10b5-1 A $25.3K 269 $94.12
2026-03-31 Clancy Paul J Grant 10b5-1 A $24.9K 265 $94.12
2026-03-25 Trotta Matteo EVP, GM, Dermatology US Grant $49.5K 537 $92.23
2026-03-17 CAGNONI PABLO J President, R&D Grant $438.4K 7,166 $61.18
2026-03-17 CAGNONI PABLO J President, R&D Grant $738.9K 11,501 $64.25
2026-03-17 CAGNONI PABLO J President, R&D Grant $0 7,166 $0.00

Showing the most recent 50 of 226 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.

Methodology & FAQ

How We Track INCY Insider Transactions

Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.

What is an SEC Form 4 filing for INCYTE CORP?

Form 4 is a transaction-level disclosure that corporate insiders — officers, directors, and beneficial owners of more than 10% of a registered class of equity securities — must file with the SEC within two business days of any change in their beneficial ownership of INCYTE CORP (INCY) shares.

What is a Rule 10b5-1 trading plan?

Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.

How is "insider buying" different from a stock grant or option exercise?

An insider buy (SEC transaction code P) is an open-market purchase of INCYTE CORP (INCY) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.

How recent is the data?

Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.